NCT04770688View on ClinicalTrials.gov

Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 19, 2020

Primary Completion Date

June 20, 2024

Study Completion Date

June 20, 2024

Conditions
Non-Small Cell Lung Cancer With EGFR MutationLocally Advanced Solid TumorMetastatic CancerAdenocarcinoma of Lung
Interventions
DRUG

Osimertinib

Osimertinib, 80mg, QD, p.o.

DRUG

Anlotinib

"(Phase Ib) Anlotinib, from 8mg to10mg to 12mg, QD, p.o. from day 1 to 14 of a 21-day cycle.~(Phase IIa)Anlotinib, given at RP2D dose QD, p.o. from day 1 to 14 of a 21-day cycle."

Trial Locations (1)

200030

Shanghai Chest hospital, Shanghai

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER

NCT04770688 - Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib | Biotech Hunter | Biotech Hunter